Publications by authors named "Michael Andreeff"

Claim this Profile
C
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, Tapan M Kadia, Sanam Loghavi, Michael Andreeff

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol for isolation of lipid droplets and mitochondria from acute myeloid leukemia cells for lipidomic analysis.
Ran Zhao, Liang Zhang, Shuxin Dong, Kazuharu Kamachi, Saurabh Kumar Gupta, Michael Andreeff

STAR Protoc· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restoring p53 wild-type conformation in TP53-Y220C-mutant acute myeloid leukemia.
Bing Z Carter, Po Yee Mak, Edward Ayoub, Xiaogang Wu, Baozhen Ke, Michael Andreeff

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.
Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, Xuemei Wang, Sanam Loghavi, Michael Andreeff

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer.
Vivek Anand, Bolutyfe Oderinde, Maryam Siddiqui, Anudishi Tyagi, Jenny Borgman, Michael Andreeff

NPJ Breast Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias.
Jayastu Senapati, Marina Konopleva, Ghayas C Issa, Elias Jabbour, Tapan Kadia, Michael Andreeff

J Hematol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GD3 synthase drives resistance to p53-induced apoptosis in breast cancer by modulating mitochondrial function.
Vivek Anand, Fouad El-Dana, Natalia Baran, Jenny Borgman, Zheng Yin, Michael Andreeff

Oncogene· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML.
Kotoko Yamatani, Tatsuro Watanabe, Kaori Saito, Abdullah Khasawneh, Abhishek Maiti, Michael Andreeff

Blood Neoplasia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.
Sankalp Arora, Wei-Ying Jen, Musa Yilmaz, Indraneel Deshmukh, Jayastu Senapati, Michael Andreeff

Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome.
Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Michael Andreeff

Haematologica· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias.
Weiguo Zhang, Li Li, Muharrem Muftuoglu, Mahesh Basyal, Noriko Togashi, Michael Andreeff

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis.
Naval Daver, Jayastu Senapati, Hagop M Kantarjian, Bofei Wang, Patrick K Reville, Michael Andreeff

Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targetable dependency in therapy-resistant mutated acute myeloid leukemia.
Ahmed M Mamdouh, Fang Qi Lim, Yang Mi, Elyse A Olesinski, Cheryl Gek Teng Chan, Michael Andreeff

bioRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, Tapan M Kadia, Sanam Loghavi, Michael Andreeff

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia.
Hiroki Akiyama, Yuki Nishida, Kyung Hee Chang, Andrea D Bedoy, Muharrem Muftuoglu, Michael Andreeff

Blood Cancer J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53.
Li Li, Muharrem Muftuoglu, Edward Ayoub, Jiangxing Lv, Mahesh Basyal, Michael Andreeff

medRxiv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms.
Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Michael Andreeff

Leukemia· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway.
Amnon Peled, Michal Abraham, Hanna Wald, Ophir Hay, Shira Hagbi, Michael Andreeff

Res Sq· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol for monitoring clonal hematopoiesis in transgenic mouse models using multispectral imaging.
Priyanka Khanna, Lauren B Ostermann, Shayaun Khazaei, Ran Zhao, Michael Andreeff

STAR Protoc· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.
Guopan Yu, Weiguo Zhang, Mahesh Basyal, Yuki Nishida, Hideaki Mizumo, Michael Andreeff

Leuk Lymphoma· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y220C mutations in patients with myeloid malignancies.
Georgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi, Alex Bataller, Aaron D Goldberg, Michael Andreeff

Leuk Lymphoma· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.
Branko Cuglievan, Hagop Kantarjian, Jeffrey E Rubnitz, Todd M Cooper, C Michel Zwaan, Michael Andreeff

Leukemia· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
Hiroki Akiyama, Hagop Kantarjian, Elias Jabbour, Ghayas Issa, Fadi G Haddad, Michael Andreeff

Int J Hematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
Courtney D DiNardo, Rebecca Olin, Eunice S Wang, Barry Skikne, Joseph Rosenthal, Michael Andreeff

Cancer Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice.
Rasoul Pourebrahim, Rafael Heinz Montoya, Hiroki Akiyama, Lauren Ostermann, Shayuan Khazaei, Michael Andreeff

Cell Rep Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis